Axcella Health Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Axcella Health Inc. operates as a clinical-stage biotechnology company that develops endogenous metabolic modulator (EMM) compositions to treat complex diseases and improve health by targeting metabolic dysregulation in areas such as liver, muscle, central nervous system, and blood disorders; its lead product candidates include AXA1125, advanced in Phase 2b trials for non-alcoholic steatohepatitis (NASH) and Phase 2a for long COVID fatigue with FDA IND clearance in early 2023, and AXA1665 in Phase 2 for reducing the risk of overt hepatic encephalopathy (OHE) recurrence. Founded in 2014 and headquartered in Boston, Massachusetts, the company leverages its proprietary AXA Development Platform to engineer novel multifactorial EMM combinations, including amino acids and derivatives, engineered in specific ratios to impact multiple biological pathways simultaneously. The company primarily serves patients in the United States through non-IND clinical studies and therapeutic development programs. In late 2023, Axcella discontinued its NASH Phase 2b trial to prioritize long COVID fatigue, reduced headcount by 85%, explored strategic alternatives, faced Nasdaq delisting for non-compliance, and stockholder-approved a plan of complete liquidation and dissolution, filing its certificate of dissolution with Delaware on December 28, 2023, after which its common stock (NASDAQ: AXLA) ceased trading and transferability.
3 Pharma Stocks to Dump Before the Damage Is Done
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
Why Is Axcella Health (AXLA) Stock Down 24% Today?
Axcella Announces Reverse Stock Split Effective September 19, 2023
Why Is Axcella Health (AXLA) Stock Down 21% Today?
Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
Why Is Axcella Health (AXLA) Stock Up 280% Today?
Axcella Health stock rockets on long Covid patent win
Axcella Granted Patent for Long COVID Fatigue Treatment
Why Is Axcella Health (AXLA) Stock Up 68% Today?
Axcella Reports Second Quarter Financial Results and Provides Business Update
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Why Is Axcella Health (AXLA) Stock Up 35% Today?
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue